PPARA and metabolic dysfunction-associated steatotic liver disease: Consistent with previous studies (Ip et al., 2003; Gervois et al., 2004), our findings strengthened the mediatory role of PPARα in liraglutide ameliorated fatty accumulation, and confirm the potential of PPARα as a drug target in the management of NAFLD.